Obstet Gynecol Sci.  2018 May;61(3):404-412. 10.5468/ogs.2018.61.3.404.

Risk factors and factors affecting the severity of overactive bladder symptoms in Korean women who use public health centers

• Chae J
• Yoo EH
• Jeong Y
• Pyeon S
• Kim D

• KMID: 2416130
• DOI: http://doi.org/10.5468/ogs.2018.61.3.404

Abstract

OBJECTIVE
To investigate the prevalence, risk factors of overactive bladder (OAB) and the factors affecting the severity of OAB symptoms.
METHODS
A total 822 interviews with women aged 18-80 years who visited public health centers were conducted between April 2014 and April 2015. The questionnaire was composed of 16 questions about urinary symptoms, 14 questions about self-treatment and the use of complementary and alternative medicine, and 21 questions about socio-demographic characteristics. The diagnostic criterion for OAB is a total OAB symptom score of 3 and more, with an urgency score of 2 or more. To know the risk factors and factors affecting the severity of OAB, the multivariate logistic regression analysis was performed.
RESULTS
One hundred fifty-seven participants (19.3%) were diagnosed with OAB, of whom 10.7%, 8.1%, and 0.7% had mild, moderate, and severe OAB symptoms, respectively. In addition, the prevalence of OAB increased with age. Among all the participants, 39.1% had stress incontinence, among them 32.7% had OAB as well. The significant risk factors of OAB were identified as age, current smoking, hyperlipidemia, cardiovascular and renal disease, whereas, the factors affecting the severity of OAB were age, current smoking, and hyperlipidemia.
CONCLUSION
Those who have risk factors and factors affecting severity of OAB should be educated to increase OAB awareness and act of urinary health promotion.

Keyword

Urinary bladder, overactive; Epidemiology; Risk factors

MeSH Terms

Complementary Therapies
Epidemiology
Female
Health Promotion
Humans
Hyperlipidemias
Logistic Models
Prevalence
Public Health*
Risk Factors*
Smoke
Smoking
Urinary Bladder, Overactive*
Smoke

Figure

• 

  Fig. 1 Prevalence rates according to age. OAB, overactive bladder.

Reference

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21:167–178.

2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20:327–336.

3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50:1306–1314.

4. Lugo Salcedo F, Sánchez Borrego R. G.U.I.A.S Group. Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluación del Control de la Vejiga (CACV). Int Urogynecol J Pelvic Floor Dysfunct. 2013; 24:1559–1566.

5. Kogan MI, Zachoval R, Ozyurt C, Schafer T, Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014; 30:2119–2130.

6. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol. 2011; 29:185–190.

7. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand. 2013; 92:1208–1215.

8. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol. 2002; 168:1027–1031.

9. Richter HE, Burgio KL, Chai TC, Kraus SR, Xu Y, Nyberg L, et al. Predictors of outcomes in the treatment of urge urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20:489–497.

10. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006; 68:318–323.

11. Jeong SJ, Homma Y, Oh SJ. Korean version of the overactive bladder symptom score questionnaire: translation and linguistic validation. Int Neurourol J. 2011; 15:135–142.

12. Choo MS, Ku JH, Lee JB, Lee DH, Kim JC, Kim HJ, et al. Cross-cultural differences for adapting overactive bladder symptoms: results of an epidemiologic survey in Korea. World J Urol. 2007; 25:505–511.

13. Sang JH, Park HM. Survey on the prevalence of overactive bladder in healthy Korean postmenopausal women. J Korean Soc Menopause. 2012; 18:60–66.

14. Coyne KS, Sexton CC, Bell JA. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013; 32:230–237.

15. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 2005; 96:88–92.

16. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004; 63:17–23.

17. Koskimäki J, Hakama M, Huhtala H, Tammela TL. Association of smoking with lower urinary tract symptoms. J Urol. 1998; 159:1580–1582.

18. Tähtinen RM, Auvinen A, Cartwright R, Johnson TM 2nd, Tammela TL, Tikkinen KA. Smoking and bladder symptoms in women. Obstet Gynecol. 2011; 118:643–648.

19. Knuutinen A, Kokkonen N, Risteli J, Vähäkangas K, Kallioinen M, Salo T, et al. Smoking affects collagen synthesis and extracellular matrix turnover in human skin. Br J Dermatol. 2002; 146:588–594.

20. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990; 162:502–514.

21. Chung MS, Chuang YC, Lee JJ, Lee WC, Chancellor MB, Liu RT. Prevalence and associated risk factors of nocturia and subsequent mortality in 1,301 patients with type 2 diabetes. Int Urol Nephrol. 2014; 46:1269–1275.

22. de Boer TA, Slieker-ten Hove MC, Burger CW, Vierhout ME. The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J Pelvic Floor Dysfunct. 2011; 22:569–575.

23. Al-Shaiji TF, Radomski SB. Relationship between body mass index and overactive bladder in women and correlations with urodynamic evaluation. Int Neurourol J. 2012; 16:126–131.

24. Ohgaki K, Horiuchi K, Kondo Y. Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the overactive bladder symptom score. Urology. 2012; 79:1372–1378.

25. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol. 2013; 189:S107–S114.

26. Uzun H, Yilmaz A, Kemik A, Zorba OU, Kalkan M. Association of insulin resistance with overactive bladder in female patients. Int Neurourol J. 2012; 16:181–186.

27. Uzun H, Zorba OU. Metabolic syndrome in female patients with overactive bladder. Urology. 2012; 79:72–75.

28. Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J Urol. 2008; 179:2470–2476.

29. Tong YC, Cheng JT. Alteration of M2, 3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol. 2007; 178:1537–1542.